Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Januar 2025 10:20 ET | Quelle: Research and Markets

Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market by Disease, by Drug Class, by Distribution Channel, and by Region" report has been added to ...
24. Januar 2024 14:35 ET | Quelle: Research and Markets

Narcolepsy Drugs Industry Outlook to 2030: Emphasizing Growth in the Sodium Oxybate and Central Nervous System Stimulants Segments

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent...
10. Mai 2023 12:28 ET | Quelle: Research and Markets

Global Chronic Fatigue Syndrome Treatment Market Report 2023: Sector is Projected to Reach $68.2 Million by 2031 at a CAGR of 4.2%

Dublin, May 10, 2023 (GLOBE NEWSWIRE) -- The "Global Chronic Fatigue Syndrome Treatment Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global...
11. März 2019 06:45 ET | Quelle: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall®

NORTHVALE, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution...
08. Februar 2018 11:32 ET | Quelle: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals and SunGen Pharma File ANDA

NORTHVALE, N.J., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...